Cited by 280interferon and immune responsesCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record.

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

Open access

Harrington, K.J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., Golan, T.·2018·Annals of Oncology

DOI 10.1093/annonc/mdy424.015

Open this paper in CoChat — free account Open PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy424.015

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorted by citations

Items 201–275 of 275

Discovery of 3-(Fluoro-imidazolyl)pyridazine Derivatives as Potent STING Agonists with Antitumor Activity
Hou, H., Zhou, J., Sui, Q., Zhang, C., Su, Z., Cui, R., Shan, B., Xu, P., Chen, Z., Jiang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01873 · Cited by 8
Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models
Gruber, D. R., Cummins, E. J., Zeng, W., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0108 · Cited by 6
“Other innate immune agonists—including small-molecule STING agonists—administered either systemically or intratumorally have shown limited antitumor activity, with many displaying poor tumor retention, rapid clearance, and dose-limiting systemic immune activation (7, 8).”
Assembly of 2′,3′-Cyclic guanosine Monophosphate-Adenosine monophosphate and their spontaneous intracellular disassembly for enhanced antitumor immunity via natural STING pathway activation
Park, J. Y., Kang, M., Lim, S., Cho, H., Yang, S., Baek, S. Y., Tan, L., Song, C., Lee, M., Yeom, B., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.157037 · Cited by 6
Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Kumar, M. A., & Lowery, R. G. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220982321 · Cited by 6
Immunotherapeutic Strategies for Head and Neck Cancer
Buchwald, Z. S., & Schmitt, N. C. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.04.004 · Cited by 6
Supramolecular lipid nanoparticle reprograms tumor microenvironment by cucurbit[7]uril-based host–guest recognition for STING-activating cancer immunotherapy
Feng, Y., Yuan, Y. J., Yu, X., Li, M., Lei, J., Li, Y., Liu, Z., Qi, S., & Yu, G. (2025) · Materials Today · doi:10.1016/j.mattod.2025.11.029 · Cited by 5
An Immune Nanoenhancer Revitalizes Chemotherapeutics to Tailor Tumor‐Derived dsDNA for Anticancer Immunoengineering
Liu, Y., Li, Y., Gong, W., Zou, D., Guo, B., Zeng, Z., Li, X., Xu, Y., & Xu, X. (2025) · Advanced Materials · doi:10.1002/adma.202516524 · Cited by 5
“Recent efforts to engineer cyclic dinucleotide analogues—such as ADU-S100, MK-1454, and TAK-676—as therapeutics have faltered due to suboptimal efficacy, poor bioavailability, and intolerable systemic inflammation [13, 15–17].”
Advancements in intratumoral therapies for liver tumors
Raman, S. S., Cutler, N. R., Jj, S., Hecht, J. R., Finn, R. S., Anand, S. R., Chiang, J., & Lu, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1726128 · Cited by 5
Integrating STING activation with programmed death-ligand 1 inhibition: Novel approaches for cancer treatment
Khorramdelazad, H., Arfaei, R., Yaraghi, P., Boroumand, A., Kheyri, A., Shirzad, Z., Kheiri, F., & Bagheri, V. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105218 · Cited by 5
Nanoengineering of cyclic dinucleotide‑manganese complexes using biodegradable mesoporous silica nanoparticles for cancer metallo-immunotherapy
Rana, I., Zhang, Z., Yoon, S., Han, K., Moon, J. J., Son, S., & Nam, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114588 · Cited by 4
ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer
Cao, D., Bin, H., Fu, X., Liu, M., Niu, X., Zhai, H., & Huang, H. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08527-1 · Cited by 4
“However, current clinical trials of STING agonists, either as monotherapy or in combination with immune checkpoint PD-1/PD-L1 inhibitors, have shown less than optimal antitumor effects [18 – 20].”
The cGAS–STING pathway in cancer immunotherapy: prognostic value and therapeutic potential
Alabi, F. A., Imodoye, S. O., Adedokun, K. A., Eltokhy, M. A., Curcic, M., Okoyeocha, E., Thapa, I., Tiwari, S., Ogundele, A. V., Ayo, T. E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760947 · Cited by 5
Feedback activation of CD73-Adenosine axis attenuates the antitumor immunity of STING pathway
Fu, N., Zhang, Z., & Quan, J. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149814 · Cited by 5
Polypeptide agonists of innate immune sensors
Dion, M. Z., & Artzi, N. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01212-8 · Cited by 4
Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors
Alotaibi, F., Alshammari, K. M., Alotaibi, B. A., & Alsaab, H. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1280591 · Cited by 6
Conjugated STING-agonist nanoparticles enhance antitumor immunity in multiple tumor modelsPreprint
Dosta, P., Cryer, A. M., Dion, M. Z., Shiraishi, T., Langston, S., Lok, D. P. P., Wang, J., Harrison, S., Ferber, S., Rajendrakumar, S. K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1647238/v1 · Cited by 4
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRAS G12D/+ Trp53 −/− murine model of sarcoma
Hildebrand, K. M., Hildebrand, K., Arcila, C. S., Marritt, K., Rajwani, J., Assadzadeh, G. E., Dufour, A., Jirik, F. R., & Monument, M. J. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2534912 · Cited by 5
Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)
Shaik, R., Suthar, K., Balija, C., Aleem, S., Syeda, F. S., Syeda, S., & Begum, S. (2025) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785251362585 · Cited by 5
Precision engineering of macrophage reprogramming with RNA interference-loaded lipid nanoparticles: a game-changer in cancer immunotherapy
Gül, S., Vergnaud, J., Fay, F., & Fattal, E. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01970-1 · Cited by 3
Combination strategies with STING agonists: Current advances and future directions
Sun, K., Fu, X., Man, Y., Liu, F., Qu, Z., Ou, Y., Cheng, W., Bian, J., Li, Z., Wang, J., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178286 · Cited by 3
STING agonists as antiviral agents
Nelson, T. S., & Ma, Z. (2025) · FEBS Letters · doi:10.1002/1873-3468.70251 · Cited by 6
Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity
Wang, T., Koo, D. J., Tessier, P. M., & Thurber, G. M. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70198 · Cited by 4
“Indeed, such agonists show strong anti-cancer activity, including in cold tumors [18,19], although they also suffer from strong side effects due to broad immune activation [20,21].”
10th anniversary of discovering cGAMP: synthesis and beyond
Chen, C. (2023) · Organic Chemistry Frontiers · doi:10.1039/d2qo02033e · Cited by 3
La voie cGAS-STING
Bacar, H., & Michallet, M. (2021) · médecine/sciences · doi:10.1051/medsci/2021077 · Cited by 3
cGAS-STING pathway reprograms macrophage polarization and is highly expressed in responding tumors after neoadjuvant immunotherapy in head and neck carcinoma
An, Z., Zhang, X., Li, L., Wusiman, D., Wang, Z., Zhang, F., Zhao, X., An, C., Yin, Z., & Gao, W. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025209 · Cited by 2
cGAS-STING Signalling in the tumour microenvironment: Implications for immune surveillance and therapeutic strategies
Al-Adayleh, T. Y. M., Ahmad, W., Rahiman, S. S. F., Murugaiyah, V., Mohamed, R., Afzal, S., Al-Ramamneh, R. S., & Attiq, A. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116832 · Cited by 3
Recent progress in cGAS–STING agonist design and mechanisms of cancer immune modulation
Wang, L., Nafees, M., Fei, H., Hanif, M., & Yang, P. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00005c · Cited by 3
The Signaling Networks of TIM-3, TGF-β, and STING in Glioblastoma
Ahmady, F., Carnie, B. M. H., Anderson, G. E. C., Achari, E., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2026) · Cells · doi:10.3390/cells15110991 · Cited by 2
Updates on intratumoral therapies in melanoma
Ma, V. T.-L., Steimle, A. K., Patel, et al. (2026) · Cancer · doi:10.1002/cncr.70400 · Cited by 2
Therapeutic targeting of the cGAS-STING pathway in human disease
Mahajan, A. S., Forsyth, C. M., Phung, C. D., Shen, X., Jarvis, R., & Stegh, A. H. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204547 · Cited by 4
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Haugh, A. M., & DAUD, A. I. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000709 · Cited by 2
Exploring shared targets in cancer immunotherapy and cancer-induced bone pain: Insights from preclinical studies
Zhang, R., Yang, Y., Li, X., Jiao, C., Lou, M., Mi, W., Mao‐Ying, Q., Chu, Y., & Wang, Y.-Q. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217399 · Cited by 2
AlbiCDN: albumin-binding amphiphilic STING agonists augment the immune activity for cancer immunotherapy
Zhuo, S., Chen, X., Zhao, L., Wang, T., Su, J., Yang, T., Yang, L., Dong, F., Zhao, Y., & Li, Y. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00475b · Cited by 1
In silico and in vitro analysis of the genotoxic and mutagenic potential of STING modulators
Vishwakarma, S., Dinavahi, S. S., Nikam, K. R., Ranjan, B., Rangaiah, R., Karunyaa, M., Anupreetha, V., Ramakrishnan, A., & Dhakshinamoorthy, S. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.04.012 · Cited by 1
Carriers Multimerize STING Protein Fragments to Activate Type I Interferon Signaling in STING-Deficient Cancer Cells
Kaskow, J. A., & Hammond, P. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00226 · Cited by 2
STING agonism in brain tumours: mechanisms, challenges, and therapeutic advances
Ioannou, Z., Cressey, P., Ahmed, M. H., Pouliopoulos, A. N., Hargrave, D. R., & Thanou, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1679361 · Cited by 1
STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma
Nelson, T. S., Pacini, C., Nguyen, A., Zeigler, T. M., Ziff, A., Paulsen, K., Simpson, A., Bhaduri‐McIntosh, S., & Ma, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1823240 · Cited by 1
Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice
Wang, J., & Jiang, R. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.03 · Cited by 1
TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy
Hu, K., Wang, J., Zhang, W., Wu, Z., Chen, J., He, Y., Duan, X., He, Y., Xin, X., Xiang, H., et al. (2026) · Advanced Science · doi:10.1002/advs.202523182 · Cited by 2
mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity
Zeng, Y., Xu, J., Wang, J., Xue, L., Liu, J., Geisler, H. C., Xu, M., Melamed, J. R., Shi, Q., Padilla, M. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525718123 · Cited by 1
Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene
Maddess, M. L., McIntosh, J. A., & Chang, W. (2022) · ACS symposium series · doi:10.1021/bk-2022-1423.ch001 · Cited by 1
Novel Targets in Development for Advanced Renal Cell Carcinoma
Thapa, B., Nelson, A. A., & Kilari, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_14 · Cited by 1
New Therapies on the Horizon
Cooper, A. J., & Heist, R. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.004 · Cited by 1
Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumorsPreprint
Wolf, N. K., Blaj, C., Picton, L. K., Snyder, G., Zhang, L., Nicolai, C. J., Ndubaku, C. O., McWhirter, S. M., García, K. C., & Raulet, D. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.02.465022 · Cited by 1
CYCLIC DINUCLEOTIDES
Wang, Z., Ma, D., & Xi, Z. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch2 · Cited by 1
New and promising immune oncology drugs combinations
Волков, Н. М. (2021) · Practical oncology · doi:10.31917/2201022
素顔の商店街・巣鴨地蔵通り (特集生活保障の視点から買い物難民問題を考える)
田中, 彰. (2011) · 福祉のひろば
Data from Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer
Huang, K., Chandra, D., McGrath, S., Dixit, V. S., Zhang, C., Wu, J., TenDyke, K., Yao, H., Hukkanen, R. R., Taylor, N., et al. (2023) · doi:10.1158/1535-7163.c.6543267.v1
Immunotherapy and Cancer Stem Cells
Suryaprakash, R. T. C., Safi, M. A. A., Alonazi, N. A., Alsieedi, A. A., & Kujan, O. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124606123010007
Targeting the STING Pathway in Breast Cancer
Nikitin, B. M., Chun, B., Urba, W. J., Bennetts, L., & Page, D. B. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_41
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Jiang, X., & Lin, W. (2025) · Angewandte Chemie · doi:10.1002/ange.202423280 · Cited by 1
Common Signaling Pathways in Cancer and Alzheimer's Disease May Point to New Treatments
Wu, C., Jiang, L., Zhong, Y., & Liu, Z. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266340314250303003647
cGAS-STING signaling in melanoma: regulation and therapeutic targeting
Jiang, T., & Fei, L. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04141-8 · Cited by 1
“The clinical results from these studies indicate that MK-1454 has the potential to address resistance to PD-1 blockade in certain patients (Harrington et al. 2018; Gogoi et al. 2020).”
TREX1 , a predator for treating MSI ‐H tumors?
Benidovskaya, E., Deneft, J., & den Eynde, M. V. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70173
Additional file 2 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778327
Additional file 3 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778330
Additional file 6 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778339
Additional file 1 of Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy
He, Q., Zheng, R., Ma, J., Zhao, L., Shi, Y., & Qiu, J. (2023) · Figshare · doi:10.6084/m9.figshare.22639602
Additional file 7 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778342
Additional file 5 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778336
Additional file 1 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778324
Additional file 4 of Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma
Zhu, C., Li, J., Yao, M., & Fang, C. (2021) · Figshare · doi:10.6084/m9.figshare.16778333
Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors
Patel, M., der Jeught, K. V., & Datta, J. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.004
Nanotechnology-driven STING regulation for on-demand therapy
Mu, Q., Huang, Q., Deng, H., Liu, G., & Liu, C. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.005
Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy
Zhou, W., Li, Y., Sun, X., Yang, H., Shi, X., Yao, L., Jiang, J., Wang, E., Wang, H., Wei, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202523722 · Cited by 1
“When combined with the PD-1 monoclonal antibody pembrolizumab, partial responses were observed in only 24% of patients with advanced solid tumors or lymphomas who received treatment [ 54 ].”
The game changer in the cervical cancer therapeutic landscape: immunotherapy
Yarza, R., Fariñas-Madrid, L., García-Durán, C., García-Illescas, D., Mazzeo, R., Giannubilo, I., & Oaknin, A. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2647581
Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy
Kaskow, J. A., Bacchus, A., Gomerdinger, V. F., Berger, A. G., Li, Z., Gerton, T. J., Smith, M. A., Li, A., Treese, J., Kindopp, A., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103251
Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation
Adrados, A., Pérez‐Fernández, J., García-Vicente, R., Garrote-de-Barros, A., Martínez‐López, J., Linares, M., & Hernández‐Sánchez, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805129
Self-assembled supramolecular nanoparticles of α-mangostin for targeted STING activation and enhanced tumor immunotherapy
Miao, J., Liu, Y., Chen, S., Zhou, Y., Liu, J., Xu, D., Mo, X., Wang, J., Zhu, Q., Yu, C., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.044
“Although several CDNs and non-CDN STING agonists exhibit potent STING activation in preclinical studies, their therapeutic efficacy as monotherapy in human clinical trials has been disap-pointing, such as ADU-S100 and MK1454 13-15 .”
An Insight into the cGAS–STING Pathway Modulation by Metal Complexes to Initiate Immunogenic Cell Death in Cancer
Ghosh, S., Mukherjee, S., & Mukherjee, A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00727
STING agonist profiling by nucleotide library defines structural determinants of cyclic dinucleotide recognition
Bekere, I., Hubarzhevska, Y., Egender, S. V., Quoika, P. K., Öllinger, R., Schrimpf, M. R., Rad, R., Zacharias, M., & Mann, C. C. D. O. (2026) · iScience · doi:10.1016/j.isci.2026.117179
The cGAS/STING pathway in cancer: translating innate DNA sensing into therapeutic potential
Wang, Y., Angulo-Lozano, J. C., Wang, Y., & Deng, L. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204552 · Cited by 2
Myeloid-Mediated Immunoregulation and Resistance to Immune Checkpoint Inhibitor Therapy Across Squamous Cell Carcinomas: Mechanisms and Reprogramming Strategies
Hadi, J. A., Nizami, Z. N., Noor, A. T., Osman, A. A., & Myers, J. N. (2026) · Cancers · doi:10.3390/cancers18172724
“…the competing agent ADU-S100 produced partial responses in fewer than 10% of patients across tumor types in its first-in-human trial, and its combination with pembrolizumab in first-line recurrent/metastatic HNSCC did not proceed to the efficacy data stage reported for MK-1454/ulevostinag [142].”
Context-Dependent cGAS-STING Activation Shapes Metastatic Progression and Dormancy
Akter-Yasuoka, E., 이탁, Murayama, T., & Nakayama, J. (2026) · Cells · doi:10.3390/cells15171619
Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy
Chen, L., Song, M.-H., Jin, M., Jin, H., Gong, L., Feng, J., Hao, Y., Shao, H., Gong, X., Gao, Z., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115372

Authors: Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T.
Affiliations: Institute of Cancer Research (GB)
Mount Sinai Hospital (US)
Columbia University Irving Medical Center (US)
Mary Crowley Cancer Research Center (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Institut Gustave Roussy (FR)
Sheba Medical Center (IL)
ORCID: Harrington, K.J.
Brody, J.
Strauss, J.
Khilnani, A.
Marabelle, A.
Golan, T.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2018-10
Volume: 29
Pages: viii712
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdy424.015
OpenAlex: W2898106814
Cited by: 280
References: 0
Citations by year: 2026: 34 · 2025: 50 · 2024: 37 · 2023: 28 · 2022: 42 · 2021: 50 · 2020: 18 · 2019: 20
FWCI: 9.57
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 483 d)
Locations: Annals of Oncology (publishedVersion)
Funders: Amgen
Pfizer
AstraZeneca
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: STING agonist, cyclic dinucleotides, pembrolizumab, immune checkpoint inhibitor combination, advanced solid tumors, lymphoma, antitumor immunity, intratumoral administration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cited by

Related

Metadata

Record

About these checks